Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, Karen Joy, Ibrahim, Ashraf S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711534/
https://www.ncbi.nlm.nih.gov/pubmed/33105672
http://dx.doi.org/10.3390/jof6040239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711534/
https://www.ncbi.nlm.nih.gov/pubmed/33105672
http://dx.doi.org/10.3390/jof6040239

Ejemplares similares